In addition, EphA2 expression is associated with EGFR inhibitor-resistant lung cancer cells, and combined treatment of EGFR and EphA2 targeted therapy is more effective than monotherapy in colorectal cancer and lung cancer [12, 13]. Here, EPHA2 is linked to lung carcinoma.